Worth reading
34Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.This transaction
Dissolution of a subsidiaryDisclosing companySoiken Holdings Inc.
Date of board resolution12 August 2026
Execution Date / Effective Date12 August 2026 (dissolution date). The date of completion of liquidation has not been determined
Target company
Research and development, manufacture and sale, and export of cosmetics
Location Toyonaka, Osaka PrefectureShare capital ¥53 millionDate of incorporation 7 November 1997
Net Sales¥904.226 million (fiscal year ended June 2026)
Operating profit-¥31.477 million (fiscal year ended June 2026)
Net income for the current fiscal year¥9.14 million (fiscal year ended June 2026)
Net assets¥102.27 million (fiscal year ended June 2026)
Impact on Business Performance
The impact on results for the fiscal year ending June 2027 is expected to be immaterial
Procedures and assumptions
Conditions Precedent to ExecutionApproval at an extraordinary general meeting of shareholders of the subsidiary (12 August 2026)
Management structure after acquisitionAll business activities ended on 31 March 2026. The cosmetics business involving placenta products was transferred to 日本予防医薬株式会社 and continues under that company. The date of completion of liquidation has not been determined
| Item | Details |
|---|---|
| Transaction name | Dissolution of a subsidiary |
| Name of the Subject Company | 株式会社ビービーラボラトリーズ |
| Business Description of the Subject Company | Research and development, manufacture and sale, and export of cosmetics |
| Location of the Subject Company | Toyonaka, Osaka Prefecture |
| Capital Stock of the Subject Company | ¥53 million |
| Date of Establishment of the Subject Company | 7 November 1997 |
| Net Sales of the Subject Company | ¥904.226 million (fiscal year ended June 2026) |
| Operating Profit of the Subject Company | -¥31.477 million (fiscal year ended June 2026) |
| Net Income of the Subject Company | ¥9.14 million (fiscal year ended June 2026) |
| Net Assets of the Subject Company | ¥102.27 million (fiscal year ended June 2026) |
| Voting rights ownership percentage | Before 100％ (after not disclosed) |
| Impact on Business Performance | The impact on results for the fiscal year ending June 2027 is expected to be immaterial |
| Date of board resolution | 12 August 2026 |
| Execution Date / Effective Date | 12 August 2026 (dissolution date). The date of completion of liquidation has not been determined |
| Conditions Precedent to Execution | Approval at an extraordinary general meeting of shareholders of the subsidiary (12 August 2026) |
| Management structure after acquisition | All business activities ended on 31 March 2026. The cosmetics business involving placenta products was transferred to 日本予防医薬株式会社 and continues under that company. The date of completion of liquidation has not been determined |
Items this document does not state (16)
Counterparty nameAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Contract DateValuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The dissolution was carried out after the Company withdrew from the Chinese market and terminated all business activities of the subsidiary as part of structural reforms, including optimization of the business portfolio, aimed at sustainable growth and improved profitability. The transfer of the domestic cosmetics business involving placenta products and various procedures associated with terminating the business had also been completed, and the Company therefore decided to dissolve the subsidiary.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.